Corvus Pharmaceuticals Stock Revenue
| CRVS Stock | USD 4.69 0.03 0.64% |
Corvus Pharmaceuticals fundamentals help investors to digest information that contributes to Corvus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Corvus Stock. The fundamental analysis module provides a way to measure Corvus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Corvus Pharmaceuticals stock.
| Last Reported | Projected for Next Year |
Corvus | Revenue |
Corvus Pharmaceuticals Company Revenue Analysis
Corvus Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Corvus
Projected quarterly revenue analysis of Corvus Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Corvus Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Corvus Pharmaceuticals' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Corvus Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Corvus Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Corvus Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Corvus Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Corvus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Corvus Pharmaceuticals by comparing valuation metrics of similar companies.Corvus Pharmaceuticals is currently under evaluation in revenue category among its peers.
Corvus Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Corvus Pharmaceuticals from analyzing Corvus Pharmaceuticals' financial statements. These drivers represent accounts that assess Corvus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Corvus Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 104.9M | 100.9M | 39.6M | 84.5M | 97.2M | 140.7M | |
| Enterprise Value | 90.8M | 41.1M | 29.0M | 73.3M | 84.3M | 80.6M |
Corvus Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Corvus Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Corvus Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Corvus Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Corvus Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Corvus Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Corvus Pharmaceuticals' value.| Shares | Goldman Sachs Group Inc | 2024-12-31 | 584.5 K | Geode Capital Management, Llc | 2024-12-31 | 566.9 K | Sphera Funds Management Ltd. | 2024-12-31 | 500.5 K | Ghost Tree Capital, Llc | 2024-09-30 | 500 K | Qube Research & Technologies | 2024-12-31 | 450.1 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 397.4 K | Renaissance Technologies Corp | 2024-12-31 | 390.7 K | State Street Corp | 2024-12-31 | 205.5 K | Millennium Management Llc | 2024-12-31 | 154.9 K | Orbimed Advisors, Llc | 2024-12-31 | 6.9 M | Samlyn Capital, Llc | 2024-12-31 | 6.7 M |
Corvus Fundamentals
| Return On Equity | -2.0 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 261.35 M | ||||
| Shares Outstanding | 64.26 M | ||||
| Shares Owned By Insiders | 3.44 % | ||||
| Shares Owned By Institutions | 58.77 % | ||||
| Number Of Shares Shorted | 5.73 M | ||||
| Price To Earning | (5.64) X | ||||
| Price To Book | 24.39 X | ||||
| EBITDA | (26.88 M) | ||||
| Net Income | (27.03 M) | ||||
| Cash And Equivalents | 56.72 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.37 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 5.80 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (23.93 M) | ||||
| Short Ratio | 10.26 X | ||||
| Earnings Per Share | (0.99) X | ||||
| Target Price | 14.8 | ||||
| Number Of Employees | 28 | ||||
| Beta | 0.91 | ||||
| Market Capitalization | 303.29 M | ||||
| Total Asset | 45.55 M | ||||
| Retained Earnings | (334.72 M) | ||||
| Working Capital | 21.09 M | ||||
| Current Asset | 78.53 M | ||||
| Current Liabilities | 6.42 M | ||||
| Net Asset | 45.55 M |
About Corvus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Corvus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corvus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corvus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.